文献速递消化道出血消化内镜

内镜控制高危消化性溃疡出血后预防性血管造影栓塞:一项随机对照试验

Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial.
PubMed 文献 · Gut · 2018-05-25

研究纳入内镜止血后的高危胃十二指肠溃疡出血患者,随机接受附加血管造影栓塞或标准治疗,主要终点为30天内再出血。意向性分析显示两组再出血率无显著差异(10.2% vs 11.4%,HR 1.14),附加栓塞未减少再出血。

要点

  • 内镜止血后附加血管造影栓塞未降低30天内再出血率(10.2% vs 11.4%,HR 1.14,95%CI 0.53-2.46,p=0.745)。
  • 符合方案分析中栓塞组再出血6.2% vs 标准治疗组11.4%(HR 1.89,95%CI 0.73-4.92,p=0.192),无显著差异。
  • 事后分析提示栓塞仅使溃疡≥15 mm患者再出血减少(4.5% vs 23.1%,p=0.027)。

核心结论

  • 内镜止血后附加血管造影栓塞不能减少高危消化性溃疡患者的再出血。

研究设计与样本

  • 随机对照试验,2010年1月至2014年7月共随机241例患者(附加血管造影栓塞组n=118,标准治疗组n=123)。
  • 纳入标准为内镜止血后胃十二指肠溃疡出血且至少符合一项:溃疡≥20 mm、喷射性出血、低血压休克或血红蛋白<9 g/dL。
  • 主要终点为30天内再出血。

主要发现

  • 意向性分析:栓塞组12例(10.2%)vs 标准治疗组14例(11.4%)达到主要终点(HR 1.14,95%CI 0.53-2.46,p=0.745)。
  • 再干预率(13 vs 17,p=0.510)和死亡率(3 vs 5,p=0.519)两组相似。
  • 符合方案分析:栓塞组96例中6例(6.2%)再出血 vs 标准治疗组123例中14例(11.4%)(HR 1.89,95%CI 0.73-4.92,p=0.192)。
  • 符合方案分析:栓塞组96例中无死亡 vs 标准治疗组5例(4.1%)死亡(p=0.108)。
  • 事后分析:栓塞仅使溃疡≥15 mm患者再出血减少(2例(4.5%)vs 12例(23.1%),p=0.027)。

关键数值与推荐

  • 高危标准:溃疡≥20 mm、喷射性出血、低血压休克或血红蛋白<9 g/dL。
  • 主要终点为30天内再出血。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 118例随机至血管造影组患者中22例(18.6%)未接受栓塞。
  • 事后分析提示栓塞仅使溃疡≥15 mm患者再出血减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In the management of patients with bleeding peptic ulcers, recurrent bleeding is associated with high mortality. We investigated if added angiographic embolisation after endoscopic haemostasis to high-risk ulcers could reduce recurrent bleeding. DESIGN: After endoscopic haemostasis to their bleeding gastroduodenal ulcers, we randomised patients with at least one of these criteria (ulcers≥20 mm in size, spurting bleeding, hypotensive shock or haemoglobin<9 g/dL) to receive added angiographic embolisation or standard treatment. Our primary endpoint was recurrent bleeding within 30 days. RESULTS: Between January 2010 and July 2014, 241 patients were randomised (added angiographic embolisation n=118, standard treatment n=123); 22 of 118 patients (18.6%) randomised to angiography did not receive embolisation. In an intention-to-treat analysis, 12 (10.2%) in the embolisation and 14 (11.4%) in the standard treatment group reached the primary endpoint (HR 1.14, 95% CI 0.53 to 2.46; p=0.745). The rate of reinterventions (13 vs 17; p=0.510) and deaths (3 vs 5, p=0.519) were similar. In a per-protocol analysis, 6 of 96 (6.2%) rebled after embolisation compared with 14 of 123 (11.4%) in the standard treatment group (HR 1.89, 95% CI 0.73 to 4.92; p=0.192). None of 96 patients died after embolisation compared with 5 (4.1%) deaths in the standard treatment group (p=0.108). In a posthoc analysis, embolisation reduced recurrent bleeding only in patients with ulcers≥15 mm in size (2 (4.5%) vs 12 (23.1%); p=0.027). CONCLUSIONS: After endoscopic haemostasis, added embolisation does not reduce recurrent bleeding. TRIAL REGISTRATION NUMBER: NCT01142180.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lau JYW, Pittayanon R, Wong KT, et al. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. Gut. 2018. PMID: 29802172. doi:10.1136/gutjnl-2018-316074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。